A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

NCT02207374 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

601

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: semaglutide
DRUG: DPP-4 inhibitor

Sponsor

Novo Nordisk A/S